Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 8.5% (PH6) vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Amino acids provide substrates for protein synthesis and metabolic processes; dextrose supplies glucose for energy; electrolytes maintain fluid and electrolyte balance.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
Intravenous infusion: 500 mL/day initially, titrate to provide 1.5-2 g/kg/day of amino acids and 25-50 g/kg/day of dextrose; monitor electrolytes.
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
Amino acids: 0.5-2 hours (rapid clearance); dextrose: ~1-2 hours (insulin-dependent). Clinical context: Continuous IV infusion maintains steady state.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Renal (amino acids: ~80% reabsorbed, excess excreted unchanged; dextrose: primarily metabolized, small fraction excreted renally <5%; electrolytes: renal excretion proportional to intake and plasma levels).
Category C
Category C
Amino Acid Solution
Amino Acid Solution